CYRAMZA ramucirumab 500 mg/50 mL solution for intravenous infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

cyramza ramucirumab 500 mg/50 ml solution for intravenous infusion vial

eli lilly australia pty ltd - ramucirumab, quantity: 500 mg - injection, intravenous infusion - excipient ingredients: histidine; histidine hydrochloride monohydrate; water for injections; glycine; sodium chloride; polysorbate 80 - cyramza , in combination with paclitaxel, is indicated for the treatment of adult patients with advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluropyrimidine chemotherapy. cyramza, as monotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy when treatment in combination with paclitaxel is not appropriate.

CYRAMZA ramucirumab 100 mg/10 mL solution for intravenous infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

cyramza ramucirumab 100 mg/10 ml solution for intravenous infusion vial

eli lilly australia pty ltd - ramucirumab, quantity: 100 mg - injection, intravenous infusion - excipient ingredients: sodium chloride; polysorbate 80; glycine; histidine hydrochloride monohydrate; water for injections; histidine - cyramza , in combination with paclitaxel, is indicated for the treatment of adult patients with advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluropyrimidine chemotherapy. cyramza, as monotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy when treatment in combination with paclitaxel is not appropriate.

B. BRAUN MIDAZOLAM midazolam (as hydrochloride) 50 mg/50 mL Injection, Intravenous Infusion bottle Australia - English - Department of Health (Therapeutic Goods Administration)

b. braun midazolam midazolam (as hydrochloride) 50 mg/50 ml injection, intravenous infusion bottle

b braun australia pty ltd - midazolam hydrochloride, quantity: 1.112 mg/ml (equivalent: midazolam, qty 1 mg/ml) - injection, intravenous infusion - excipient ingredients: hydrochloric acid; sodium chloride; water for injections - iv as an agent for conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with a narcotic; iv for induction of anaesthesia, preliminary to administration of other anaesthetic agents. with the use of a narcotic premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time; iv for sedation in intensive care units; intermittent administration or continuous infusion; im for preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.

B. BRAUN MIDAZOLAM midazolam (as hydrochloride) 100 mg/100 mL Injection, Intravenous Infusion bottle Australia - English - Department of Health (Therapeutic Goods Administration)

b. braun midazolam midazolam (as hydrochloride) 100 mg/100 ml injection, intravenous infusion bottle

b braun australia pty ltd - midazolam hydrochloride, quantity: 1.112 mg/ml (equivalent: midazolam, qty 1 mg/ml) - injection, intravenous infusion - excipient ingredients: hydrochloric acid; sodium chloride; water for injections - iv as an agent for conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with a narcotic; iv for induction of anaesthesia, preliminary to administration of other anaesthetic agents. with the use of a narcotic premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time; iv for sedation in intensive care units; intermittent administration or continuous infusion; im for preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.

BAXTER POTASSIUM CHLORIDE 40 mmol and 0.9% SODIUM CHLORIDE 100 mL intravenous infusion bag Australia - English - Department of Health (Therapeutic Goods Administration)

baxter potassium chloride 40 mmol and 0.9% sodium chloride 100 ml intravenous infusion bag

baxter healthcare pty ltd - potassium chloride, quantity: 29.8 g/l; sodium chloride, quantity: 9 g/l - injection, intravenous infusion - excipient ingredients: water for injections - the baxter potassium chloride and sodium chloride intravenous infusion is indicated as a source of water and to restore electrolyte balance as required by the patient's clinical condition, such as hypokalaemia.

BAXTER POTASSIUM CHLORIDE 10 mmol and 0.29% SODIUM CHLORIDE 100 mL intravenous infusion bag Australia - English - Department of Health (Therapeutic Goods Administration)

baxter potassium chloride 10 mmol and 0.29% sodium chloride 100 ml intravenous infusion bag

baxter healthcare pty ltd - sodium chloride, quantity: 2.92 g/l; potassium chloride, quantity: 7.46 g/l - injection, intravenous infusion - excipient ingredients: water for injections - the baxter potassium chloride and sodium chloride intravenous infusion is indicated as a source of water and to restore electrolyte balance as required by the patient's clinical condition, such as hypokalaemia.

OLICLINOMEL N7-1000 E 2500 mL IV emulsion for infusion with electrolytes bag Australia - English - Department of Health (Therapeutic Goods Administration)

oliclinomel n7-1000 e 2500 ml iv emulsion for infusion with electrolytes bag

baxter healthcare pty ltd - olive oil; soya oil - injection, intravenous infusion - excipient ingredients: glycerol; sodium hydroxide; ascorbyl palmitate; egg lecithin; sodium oleate; water for injections - parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.

OLICLINOMEL N7-1000 2500mL IV emulsion for infusion without electrolytes bag Australia - English - Department of Health (Therapeutic Goods Administration)

oliclinomel n7-1000 2500ml iv emulsion for infusion without electrolytes bag

baxter healthcare pty ltd - soya oil; olive oil - injection, intravenous infusion - excipient ingredients: water for injections; egg lecithin; ascorbyl palmitate; sodium hydroxide; glycerol; sodium oleate - parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.

OLICLINOMEL N6-900 E 2500 mL IV emulsion for infusion with electrolytes bag Australia - English - Department of Health (Therapeutic Goods Administration)

oliclinomel n6-900 e 2500 ml iv emulsion for infusion with electrolytes bag

baxter healthcare pty ltd - olive oil; soya oil - injection, intravenous infusion - excipient ingredients: sodium hydroxide; ascorbyl palmitate; egg lecithin; water for injections; sodium oleate; glycerol - parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.

OLICLINOMEL N6-900 2500mL IV emulsion for infusion without electrolytes bag Australia - English - Department of Health (Therapeutic Goods Administration)

oliclinomel n6-900 2500ml iv emulsion for infusion without electrolytes bag

baxter healthcare pty ltd - olive oil; soya oil - injection, intravenous infusion - excipient ingredients: sodium hydroxide; ascorbyl palmitate; egg lecithin; water for injections; glycerol; sodium oleate - parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.